Aptar Pharma Receives CE Mark for Intranasal Vaccination Device

Key Facts

1Aptar Pharma has received the CE Mark for its innovative intranasal vaccination device.

Aptar Pharma has received the CE Mark for its innovative intranasal vaccination device. Investing.com reported that this certification allows for the sale and use of the new medical device within the European Economic Area, specifically designed for needle-free vaccine delivery.

The certification confirms that the device meets European safety, health, and environmental protection requirements. This regulatory milestone facilitates market entry for the company's pharmaceutical solutions in a major international market, which is expected to impact future revenue growth.